A study from Rutgers University suggests that GLP-1 receptor agonist drugs, the class that includes Ozempic (semaglutide) and Wegovy, may weaken the link between impulsive tendencies and violent behavior. The finding adds a surprising dimension to the already-expanding research literature on GLP-1 drugs, which were initially approved for type 2 diabetes and later for weight loss and are now being studied for effects on addiction, cognitive function, and psychiatric conditions.

The Rutgers research found that people with high impulsivity who were taking GLP-1 drugs showed reduced associations between their impulsive personality traits and actual violent behavior compared to impulsive individuals not taking the drugs. The proposed mechanism involves GLP-1’s effect on dopamine systems in the brain, the same pathways that regulate reward-seeking, impulse control, and addiction.

What GLP-1 Drugs Are

GLP-1 (glucagon-like peptide-1) receptor agonists were first developed as diabetes treatments because they stimulate insulin secretion in response to meals and reduce blood sugar. The FDA approved semaglutide (Ozempic) for type 2 diabetes in 2017 and a higher-dose version (Wegovy) for obesity management in 2021. Other drugs in the class include liraglutide (Victoza/Saxenda) and tirzepatide (Mounjaro/Zepbound).

GLP-1 receptors are not only found in the pancreas. They are also expressed in the brain, particularly in regions including the hypothalamus, brainstem, and limbic system areas including the nucleus accumbens, a central node in the brain’s reward and impulse control circuitry. This brain distribution is what makes researchers interested in behavioral effects beyond blood sugar and weight.

The Rutgers Study

The Rutgers team designed the study to specifically test whether GLP-1 drugs moderate the relationship between impulsivity and aggression. Impulsivity is one of the strongest individual predictors of violent behavior: people with high impulsivity have more difficulty inhibiting responses, especially under emotional or frustration-related provocation.

The study found that GLP-1 drugs appeared to buffer this relationship, meaning people with the same high-impulsivity traits showed less actual violent behavior when taking GLP-1 drugs compared to similarly impulsive people not on the drugs. The research did not find that GLP-1 drugs directly reduced aggression in all users, only that they attenuated the impulsivity-to-violence pathway specifically.

Proposed Brain Mechanism

The proposed mechanism draws on existing research showing that GLP-1 drugs reduce addictive and compulsive behaviors in animal and human studies. Patients taking semaglutide have reported reduced alcohol cravings, reduced gambling urges, and reduced compulsive eating behaviors, all pointing to the drug’s modulating effect on dopamine systems. Impulsive aggression involves similar dopamine-mediated failure of inhibitory control, making GLP-1’s behavioral effects a plausible extension.

The dopamine hypothesis for GLP-1’s behavioral effects is still being tested. A key question is whether the effect is direct (GLP-1 receptors in the brain directly reduce impulsive responding) or indirect (weight loss and metabolic improvement reduce stress and inflammation that amplify impulsive behavior).

What This Doesn’t Mean

The Rutgers study does not suggest that Ozempic or Wegovy should be prescribed as anti-violence medications or that they can be used to manage violent offenders. The sample is not a clinical trial with randomized assignment, meaning selection effects (people who get GLP-1 prescriptions differ from people who do not in multiple ways) could account for some findings.

The result needs replication, particularly in clinical settings with larger and more diverse populations. The practical clinical application, if the finding holds up, is most likely in populations where both metabolic conditions and impulsive behavioral problems co-occur, which is common in addiction medicine, forensic psychiatry, and correctional health settings.

The Expanding GLP-1 Research Universe

The Rutgers violence finding joins a rapidly expanding body of research showing GLP-1 drugs affecting behaviors well beyond weight and blood sugar. Studies published in 2025 and 2026 have shown associations between GLP-1 use and reduced alcohol use disorder severity, reduced opioid relapse rates, reduced Alzheimer’s progression in early disease, and improved cardiovascular outcomes beyond what weight loss alone explains.

The breadth of effects is unusual for a single drug class and reflects the wide distribution of GLP-1 receptors across body systems. Pharmaceutical researchers are investing heavily in next-generation GLP-1 combination therapies specifically targeting neurological and psychiatric applications.

Frequently Asked Questions

Can Ozempic reduce violent behavior?

A Rutgers University study suggests GLP-1 drugs like Ozempic (semaglutide) may weaken the link between impulsive personality traits and violent behavior. People with high impulsivity who were taking GLP-1 drugs showed less actual violent behavior than equally impulsive people not on the drugs. The proposed mechanism involves GLP-1’s effect on dopamine systems that regulate impulse control. This is an early research finding that needs replication and does not mean GLP-1 drugs are appropriate as anti-violence treatments.

What other behavioral effects do GLP-1 drugs have?

Beyond weight loss and blood sugar control, GLP-1 drugs have been associated in research studies with reduced alcohol cravings and use, reduced opioid relapse rates, reduced gambling urges, improved cognitive function, slowed Alzheimer’s progression in early disease, and now reduced impulsive violence. The effects are thought to operate through GLP-1 receptors in brain reward and impulse control circuits, particularly the nucleus accumbens.

What is the difference between Ozempic and Wegovy?

Ozempic and Wegovy both contain semaglutide, the same active ingredient. Ozempic is FDA-approved for type 2 diabetes management at lower doses (0.5 mg, 1 mg, 2 mg weekly injection). Wegovy is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition at a higher maximum dose (2.4 mg weekly injection). Both are manufactured by Novo Nordisk and belong to the GLP-1 receptor agonist drug class.